F Roshanzamir1,2,3, M Miraghajani4, M H Rouhani2,5, M Mansourian6, R Ghiasvand2,5, S M Safavi7,8. 1. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. 2. Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. 3. Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. 4. Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. 6. Department of Biostatistics and Epidemiology, Health School, Isfahan University of Medical Sciences, Isfahan, Iran. 7. Food Security Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. safavimorteza@yahoo.com. 8. Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran. safavimorteza@yahoo.com.
Abstract
BACKGROUND AND OBJECTIVE: Fetuin-A is a liver-derived circulating protein that is associated with insulin resistance and diabetes. The objective of this systematic review and meta-analysis of published observational studies was to investigate mean levels of fetuin-A in T2D patients and the relationship between blood fetuin-A levels and T2D risk. MATERIALS AND METHODS: PubMed, Embase, Google Scholar, Web of Science, and The Cochrane Library were systematically searched for potential relevant studies up to 1 December 2016. Natural logarithm-transformed estimate risks, standard mean differences on the basis of Hedges's adjusted g, and 95% confidence intervals (CIs) were calculated for all eligible studies and were combined to measure the pooled data using random-effects model. RESULTS: A total of 32 studies including 27 case-control and 5 cohort studies were included in the current study. Fetuin-A levels in T2D patients were significantly higher than control groups [Hedges' g = 1.73, 95% CI (1.25-2.22), P < 0.001], with significant heterogeneity across studies (P < 0.001, I 2 = 98.46%). Findings from meta-analyses of cohort studies showed a statistically significant association between fetuin-A levels and T2D risk [rate ratio = 1.62, 95% CI (1.26-2.08), P < 0.001], with no significant heterogeneity (P = 0.10, I 2 = 46.06%). CONCLUSION: We found a significant relationship between the fetuin-A levels with T2D risk. Although fetuin-A may be as a potential screening and prediction biomarker or a therapeutic target in T2D patients, further studies are required in this regard.
BACKGROUND AND OBJECTIVE:Fetuin-A is a liver-derived circulating protein that is associated with insulin resistance and diabetes. The objective of this systematic review and meta-analysis of published observational studies was to investigate mean levels of fetuin-A in T2D patients and the relationship between blood fetuin-A levels and T2D risk. MATERIALS AND METHODS: PubMed, Embase, Google Scholar, Web of Science, and The Cochrane Library were systematically searched for potential relevant studies up to 1 December 2016. Natural logarithm-transformed estimate risks, standard mean differences on the basis of Hedges's adjusted g, and 95% confidence intervals (CIs) were calculated for all eligible studies and were combined to measure the pooled data using random-effects model. RESULTS: A total of 32 studies including 27 case-control and 5 cohort studies were included in the current study. Fetuin-A levels in T2D patients were significantly higher than control groups [Hedges' g = 1.73, 95% CI (1.25-2.22), P < 0.001], with significant heterogeneity across studies (P < 0.001, I 2 = 98.46%). Findings from meta-analyses of cohort studies showed a statistically significant association between fetuin-A levels and T2D risk [rate ratio = 1.62, 95% CI (1.26-2.08), P < 0.001], with no significant heterogeneity (P = 0.10, I 2 = 46.06%). CONCLUSION: We found a significant relationship between the fetuin-A levels with T2D risk. Although fetuin-A may be as a potential screening and prediction biomarker or a therapeutic target in T2D patients, further studies are required in this regard.
Entities:
Keywords:
Fetuin-A; Meta-analysis; Type 2 diabetes
Authors: Diego Pérez-Sotelo; Arturo Roca-Rivada; María Larrosa-García; Cecilia Castelao; Iván Baamonde; Javier Baltar; Ana Belen Crujeiras; Luisa María Seoane; Felipe F Casanueva; María Pardo Journal: Endocrine Date: 2016-10-14 Impact factor: 3.633
Authors: Suresh T Mathews; Sanjay Rakhade; Xiaohua Zhou; Graham C Parker; Donald V Coscina; George Grunberger Journal: Biochem Biophys Res Commun Date: 2006-09-25 Impact factor: 3.575
Authors: Marcel Roos; Dimitrios Oikonomou; Maximilian von Eynatten; Peter B Luppa; Uwe Heemann; Jens Lutz; Marcus Baumann; Peter P Nawroth; Angelika Bierhaus; Per M Humpert Journal: Cardiovasc Diabetol Date: 2010-09-07 Impact factor: 9.951
Authors: Janine Kröger; Karina Meidtner; Norbert Stefan; Marcela Guevara; Nicola D Kerrison; Eva Ardanaz; Dagfinn Aune; Heiner Boeing; Miren Dorronsoro; Courtney Dow; Guy Fagherazzi; Paul W Franks; Heinz Freisling; Marc J Gunter; José María Huerta; Rudolf Kaaks; Timothy J Key; Kay Tee Khaw; Vittorio Krogh; Tilman Kühn; Francesca Romana Mancini; Amalia Mattiello; Peter M Nilsson; Anja Olsen; Kim Overvad; Domenico Palli; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Núria Sala; Elena Salamanca-Fernández; Ivonne Sluijs; Annemieke M W Spijkerman; Anne Tjonneland; Konstantinos K Tsilidis; Rosario Tumino; Yvonne T van der Schouw; Nita G Forouhi; Stephen J Sharp; Claudia Langenberg; Elio Riboli; Matthias B Schulze; Nicholas J Wareham Journal: Diabetes Date: 2018-03-09 Impact factor: 9.461
Authors: Xiongfeng Pan; Shi Wu Wen; Prince L Bestman; Atipatsa C Kaminga; Kwabena Acheampong; Aizhong Liu Journal: PLoS One Date: 2020-03-05 Impact factor: 3.240